HomeWUXAY • OTCMKTS
add
Wuxi Apptec ADR
Previous close
$13.88
Day range
$13.88 - $13.88
Year range
$5.73 - $15.95
Market cap
318.49B HKD
Avg Volume
5.83K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (CNY) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 12.06B | 15.26% |
Operating expense | 908.60M | -43.97% |
Net income | 3.51B | 53.27% |
Net profit margin | 29.15 | 32.98% |
Earnings per share | 1.24 | 61.04% |
EBITDA | 5.71B | 73.60% |
Effective tax rate | 30.88% | — |
Balance Sheet
Total assets
Total liabilities
| (CNY) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 33.68B | 139.72% |
Total assets | 94.61B | 27.44% |
Total liabilities | 23.13B | 24.01% |
Total equity | 71.47B | — |
Shares outstanding | 2.84B | — |
Price to book | 0.56 | — |
Return on assets | 14.29% | — |
Return on capital | 16.77% | — |
Cash Flow
Net change in cash
| (CNY) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | 3.51B | 53.27% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity; a subsidiary, WuXi Biologics, is one of the top five drug development companies globally by revenue. Wikipedia
Founded
Dec 1, 2000
Website
Employees
37,832
